Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple sclerosis | EFO_0003885 | D009103 | G35 |
graft vs host disease | — | D006086 | D89.81 |
Code | Description |
---|---|
J7513 | Daclizumab, parenteral, 25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney transplantation | D016030 | — | — | 1 | 1 | 5 | 6 | 1 | 13 |
Lymphoma | D008223 | — | C85.9 | 6 | 6 | — | 1 | 1 | 10 |
Uveitis | D014605 | EFO_1001231 | H20.9 | 2 | 4 | — | 1 | 1 | 8 |
Leukemia | D007938 | — | C95 | 3 | 3 | — | 1 | — | 6 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | 2 | 2 | 5 |
Graft vs host disease | D006086 | — | D89.81 | — | — | 3 | 1 | — | 4 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | — | 2 | — | 3 |
Heart transplantation | D016027 | EFO_0010673 | — | 1 | 1 | — | 2 | — | 3 |
Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 2 | 1 | — | 1 | — | 3 |
T-cell leukemia | D015458 | — | — | 2 | 1 | — | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 2 | 12 | 1 | — | — | 13 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 6 | 4 | — | 1 | 12 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | 4 | 4 | — | — | 9 |
Sclerosis | D012598 | — | — | 1 | 2 | 2 | — | 1 | 6 |
Hypoglycemia | D007003 | — | E16.2 | 1 | 4 | 1 | — | — | 5 |
Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 2 | — | — | 3 |
Immune system diseases | D007154 | — | D89.9 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hodgkin disease | D006689 | — | C81 | 3 | 4 | — | — | — | 4 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 2 | — | — | — | 3 |
Myelodysplastic syndromes | D009190 | — | D46 | — | 2 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 2 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | — | — | — | 2 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 2 | — | — | — | 2 |
Myeloid leukemia chronic-phase | D015466 | — | — | 1 | 2 | — | — | — | 2 |
Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 2 | — | — | — | 2 |
T-cell lymphoma | D016399 | — | — | 1 | 1 | — | — | — | 2 |
T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Drug therapy | D004358 | — | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Plasmapheresis | D010956 | — | — | — | — | — | — | 1 | 1 |
Hereditary congenital and neonatal diseases and abnormalities | D009358 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Daclizumab |
INN | daclizumab |
Description | Daclizumab (humanized mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >3NFS:H|Light chain of Fab fragment of daclizumab
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAY
MELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
>3NFS:L|Heavy chain of Fab fragment of daclizumab
DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPD
DFATYYCHQRSTYPLTFGQGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE |
PDB | 3NFP, 3NFS |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201605 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00111 |
UNII ID | CUJ2MVI71Y (ChemIDplus, GSRS) |